Related Experiment Video
Updated: May 14, 2026
Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
Erlotinib induced trichomegaly of the eyelashes
Sang-Hoon Jeon1, Jeong-Seon Ryu, Gwang-Seong Choi
1Department of Internal Medicine, Inha University College of Medicine, Incheon, Korea.
Abstract:
Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been widely used for non-small-cell lung cancer patients. Its untoward cutaneous effects are largely well known and developed in many patients treated with EGFR TKIs. However trichomegaly of eyelash is rarely reported. Although trichomegaly is not a drug-limiting side effect, it could be troublesome of continuing the treatment because of cosmetic issue or eyeball irritation by long eyelashes. Therefore clinicians are needed to pay attention to this uncommon effect. We herein describe erlotinib induced trichomegaly of eyelashes in a woman with adenocarcinoma of the lung.
Insights
Eyelash growth (trichomegaly) is a rare side effect of epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) used for lung cancer. This study highlights erlotinib as a cause, noting potential cosmetic and irritation issues for patients.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard treatments for non-small-cell lung cancer.
- Cutaneous side effects are common with EGFR TKIs, but eyelash changes are rarely documented.
- Trichomegaly, or excessive eyelash growth, can cause cosmetic concerns and ocular irritation, potentially impacting treatment adherence.
Purpose of the Study:
- To report a rare case of erlotinib-induced trichomegaly of eyelashes in a patient with lung adenocarcinoma.
- To raise awareness among clinicians about this uncommon but potentially bothersome side effect of EGFR TKIs.
Main Methods:
- Case report of a woman diagnosed with adenocarcinoma of the lung.
- Observation of trichomegaly of eyelashes following treatment with erlotinib.
Main Results:
- The patient developed significant eyelash growth (trichomegaly) during erlotinib therapy.
- While not a dose-limiting toxicity, the trichomegaly presented cosmetic and irritative challenges.
Conclusions:
- Erlotinib can induce trichomegaly of eyelashes, an uncommon adverse effect of EGFR TKIs.
- Clinicians should be aware of this side effect to manage patient concerns and ensure treatment continuity.